SBIR Phase I: Bioluminescence Resonance Energy Transfer Assays for Clinical Chemistry

Information

• NSF Award
• 0711621

Owner

• Zymera Corporation

• Award Id

  0711621

• Award Effective Date

  7/1/2007 - 17 years ago

• Award Expiration Date

  12/31/2007 - 17 years ago

• Award Amount

  $ 99,993.00

• Award Instrument

  Standard Grant

This Small Business Innovation Research (SBIR) Phase I research project aims to develop a point-of-care assay for creatine kinase, an important toxicity biomarker, to screen for adverse drug reactions (ADRs) using whole blood. The assay will utilize bioluminescent resonance energy transfer (BRET) probes incorporating quantum dots. <br/><br/>The proposed technology is likely to impact toxicity testing, allowing physicians to test for potential ADR at an early stage and take corrective measures. With over 50% of Medicare patients taking multiple medications, the probability of ADRs is high and any inexpensive and reliable test for toxicity would be of benefit to these individuals and society as a whole.

• Program Officer

  F.C. Thomas Allnutt

• Min Amd Letter Date

  5/17/2007 - 17 years ago

• Max Amd Letter Date

  5/17/2007 - 17 years ago

• ARRA Amount

• Name

  Zymera Corporation

• City

  San Jose

• State

  CA

• Country

  United States

• Address

  5941 Optical Court

• Postal Code

  951381400

• Phone Number

  6505157897

• First Name

  Daniel

• Last Name

  Sobek

• Email Address

  daniel_sobek@zymera.com

• Start Date

  5/17/2007 12:00:00 AM